CytoDyn Inc. CYDY
OTC PK
| 08/31/2026 | 05/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.94% | 38.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.22% | 7.82% | |||
| Operating Income | 3.22% | -7.82% | |||
| Income Before Tax | -102.15% | -110.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -102.15% | -110.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -102.15% | -110.28% | |||
| EBIT | 3.22% | -7.82% | |||
| EBITDA | 3.45% | -7.83% | |||
| EPS Basic | -96.00% | -87.50% | |||
| Normalized Basic EPS | -48.48% | 21.43% | |||
| EPS Diluted | -96.00% | -87.50% | |||
| Normalized Diluted EPS | -48.48% | 21.43% | |||
| Average Basic Shares Outstanding | 0.99% | 7.33% | |||
| Average Diluted Shares Outstanding | 0.99% | 7.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||